# Safety and Tolerability of VGR-R01 for Patients With Bietti Crystalline Dystrophy

> **NCT05694598** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Vitalgen BioPharma Co., Ltd.** · enrollment: 12 (estimated)

## Conditions studied

- Bietti Crystalline Dystrophy

## Interventions

- **GENETIC:** VGR-R01

## Key facts

- **NCT ID:** NCT05694598
- **Lead sponsor:** Shanghai Vitalgen BioPharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-27
- **Primary completion:** 2024-09-13
- **Final completion:** 2028-09-13
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05694598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05694598, "Safety and Tolerability of VGR-R01 for Patients With Bietti Crystalline Dystrophy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05694598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*